Australia should be initiating a psychedelic research program


A recent review in Pharmacological Reviews highlights that over the last decade, a renaissance has occurred in psychedelic drug research in North America and Europe as investigators at Johns Hopkins School of Medicine, University of California, Los Angeles (UCLA), New York University and Imperial College London have embarked on studies that could be paradigm-changing for psychiatry (Nichols, 2016). These developments overturn a 30-year embargo on psychedelic research that followed political reactions to the 1960s counter-culture movement in the United States and elsewhere, as disgraced Harvard Professor Timothy Leary told the world to take psychedelics to ‘turn on, tune in and drop out’. Promising research was halted, not for lack of theoretical interest and clinical applications but due to political pressure (Nutt et al., 2013).

Read the full paper:

Share this post

Innovative psychedelic research

The re-emergence of psychedelic research places a crucial emphasis on a holistic approach to mental health from pharmacology, neurobiological process, ecological connection, and therapeutic support.  PRISM supports research and clinical development of therapies where current options provide limited relief.

Your support allows us to pursue cutting edge research for next-generation mental health care.


We are a DGR-1 non-profit research charity developing medical and legal processes for the application of psychedelic medicines for improved wellbeing.


Contact Us

Send us an email and we'll get back to you soon.

Not readable? Change text. captcha txt

Start typing and press Enter to search